FR2361914A1 - Nouvelles formulations de medicaments a danger d'emploi abusif reduit - Google Patents

Nouvelles formulations de medicaments a danger d'emploi abusif reduit

Info

Publication number
FR2361914A1
FR2361914A1 FR7621071A FR7621071A FR2361914A1 FR 2361914 A1 FR2361914 A1 FR 2361914A1 FR 7621071 A FR7621071 A FR 7621071A FR 7621071 A FR7621071 A FR 7621071A FR 2361914 A1 FR2361914 A1 FR 2361914A1
Authority
FR
France
Prior art keywords
drugs
new formulations
reduced danger
abusive use
danger
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7621071A
Other languages
English (en)
Other versions
FR2361914B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of FR2361914A1 publication Critical patent/FR2361914A1/fr
Application granted granted Critical
Publication of FR2361914B1 publication Critical patent/FR2361914B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un procédé pour réduire le danger d'emploi abusif de préparations pharmaceutiques à usage entéral renfermant des analgésiques d'activité moyenne à forte. Le procédé consiste à ajouter des substances gonflantes déterminées, notamment des dérivés méthylcellulosiques qui s'opposent à l'extraction des substances actives. Une solution injectable de la substance active ne peut plus être obtenue à partir de comprimés et de dragées conformes à l'invention.
FR7621071A 1975-07-09 1976-07-09 Nouvelles formulations de medicaments a danger d'emploi abusif reduit Granted FR2361914A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2530563A DE2530563C2 (de) 1975-07-09 1975-07-09 Analgetische Arzneimittel mit vermindertem Mißbrauchspotential

Publications (2)

Publication Number Publication Date
FR2361914A1 true FR2361914A1 (fr) 1978-03-17
FR2361914B1 FR2361914B1 (fr) 1978-12-15

Family

ID=5951020

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7621071A Granted FR2361914A1 (fr) 1975-07-09 1976-07-09 Nouvelles formulations de medicaments a danger d'emploi abusif reduit

Country Status (7)

Country Link
US (1) US4070494A (fr)
JP (1) JPS5210415A (fr)
BE (1) BE843865A (fr)
CA (1) CA1064397A (fr)
DE (1) DE2530563C2 (fr)
FR (1) FR2361914A1 (fr)
GB (1) GB1517480A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154414A1 (fr) 2010-06-07 2011-12-15 Ethypharm Microgranules et microcomprimes resistants au detournement

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1207231A (fr) * 1982-08-24 1986-07-08 Hans W. Zulliger Suppositoire medicamenteux
NL9102142A (nl) * 1991-12-20 1993-07-16 Dagra Pharma Bv Zetpillen met vertraagde afgifte en werkwijze voor de bereiding daarvan.
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
AUPM814994A0 (en) * 1994-09-14 1994-10-06 Sterling Winthrop Inc. Codeine-containing formulations
ATE261302T1 (de) * 1998-05-28 2004-03-15 Krewel Meuselbach Gmbh Retardiertes schmerzmittel enthaltend tilidin
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US9820982B2 (en) * 2001-07-06 2017-11-21 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
BR0210855A (pt) * 2001-07-06 2006-10-24 Penwest Pharmaceuticals Compan Método de fabricação de formulações de liberação prolongada
US20150031718A1 (en) * 2001-08-06 2015-01-29 Purdue Pharma L.P. Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US7842307B2 (en) * 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030068276A1 (en) * 2001-09-17 2003-04-10 Lyn Hughes Dosage forms
CA2459976A1 (fr) * 2001-09-26 2003-04-03 Penwest Pharmaceuticals Company Formulations d'opioides presentant un potentiel reduit pour des utilisations abusives
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CA2464528A1 (fr) * 2001-11-02 2003-05-15 Elan Corporation, Plc Composition pharmaceutique
US20040126428A1 (en) * 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
DE60323474D1 (de) * 2002-04-09 2008-10-23 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
DE10250083A1 (de) * 2002-06-17 2003-12-24 Gruenenthal Gmbh Gegen Missbrauch gesicherte Darreichungsform
US7776314B2 (en) * 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP1374859B1 (fr) * 2002-06-28 2006-06-07 Stada Arzneimittel Ag Composition pharmaceutique solide du chlorhydrate de tilidine
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP4694207B2 (ja) 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
CA2499994C (fr) * 2002-09-23 2012-07-10 Verion, Inc. Compositions pharmaceutiques n'induisant pas l'abus
DE10250084A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DK1658054T3 (da) * 2003-08-06 2007-10-01 Gruenenthal Gmbh Indgivelsesform, som er sikret mod misbrug
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050165038A1 (en) * 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
EP1765292B1 (fr) * 2004-06-12 2017-10-04 Collegium Pharmaceutical, Inc. Formulations de prévention des abus
ITMI20041317A1 (it) * 2004-06-30 2004-09-30 Ibsa Inst Biochimique Sa Formulazioni farmaceutiche per la somministrazione sicura di farmaci utilizzati nel trattamento della tossicodipendenza e procedimento per il loro ottenimento
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
AU2005295482B2 (en) * 2004-10-15 2011-03-31 Supernus Pharmaceuticals Inc. Less abusable pharmaceutical preparations
FR2878161B1 (fr) * 2004-11-23 2008-10-31 Flamel Technologies Sa Forme medicamenteuse orale, solide et concue pour eviter le mesusage
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en) * 2004-11-24 2007-10-04 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
FR2878158B1 (fr) * 2004-11-24 2009-01-16 Flamel Technologies Sa Forme pharmaceutique orale, microparticulaire solide concue pour eviter le mesusage
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8329744B2 (en) * 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
WO2007056142A2 (fr) * 2005-11-02 2007-05-18 Theraquest Biosciences, Llc Procedes de prevention du syndrome serotoninergique et compositions utilisees a cette fin
WO2008134071A1 (fr) * 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Formulations multimodales à libération progressive résistantes aux emplois abusifs
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
FR2904225B1 (fr) * 2006-07-28 2010-08-13 Bouchara Recordati Compositions pharmaceutiques de substances actives difficilement detournables de la voie d'administration a laquelle elles sont destinees
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
EP1897543A1 (fr) 2006-08-30 2008-03-12 Euro-Celtique S.A. Gaufre de buprénorphine pour la thérapie de substitution
US8187636B2 (en) * 2006-09-25 2012-05-29 Atlantic Pharmaceuticals, Inc. Dosage forms for tamper prone therapeutic agents
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
ES2612032T3 (es) * 2007-06-04 2017-05-11 Shear/Kershman Laboratories, Inc. Formas farmacéuticas orales basadas en lípidos inviolables para agonistas opiáceos
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
CA2923102C (fr) * 2007-08-13 2019-10-15 Omeho Life Sciences Inc. Medicaments resistant aux abus, procedes d'utilisation et de fabrication
WO2009076764A1 (fr) * 2007-12-17 2009-06-25 Labopharm Inc. Formulation à libération contrôlée évitant les utilisations impropres
CA2713128C (fr) 2008-01-25 2016-04-05 Gruenenthal Gmbh Forme posologique pharmaceutique
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
BRPI0912014A2 (pt) 2008-05-09 2019-03-06 Grünenthal GmbH processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização
CN102316857A (zh) 2008-12-16 2012-01-11 莱博法姆公司 防止误用的控释配方
CN102573805A (zh) 2009-07-22 2012-07-11 格吕伦塔尔有限公司 热熔挤出的控制释放剂型
RU2015138422A (ru) 2009-07-22 2018-12-25 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
WO2011041414A1 (fr) * 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Procédés et compositions de dissuasion d'abus
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US9579285B2 (en) * 2010-02-03 2017-02-28 Gruenenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
NZ607392A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising inorganic salt
BR112013005234A2 (pt) 2010-09-02 2016-05-03 Gruenenthal Gmbh forma de dosagem resistente à violação compreendendo um polímero aniônico.
EP2826467B1 (fr) 2010-12-22 2017-08-02 Purdue Pharma L.P. Formes posologiques à libération contrôlée enchâssées et inviolables
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
PE20141638A1 (es) 2011-07-29 2014-11-22 Gruenenthal Chemie Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
RS56527B1 (sr) 2011-07-29 2018-02-28 Gruenenthal Gmbh Tableta za trenutno oslobađanje leka rezistentna na zloupotrebu
FR2983409B1 (fr) 2011-12-06 2013-12-27 Ethypharm Sa Comprime susceptible de lutter contre le detournement par voie injectable
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
TW201722406A (zh) 2012-03-02 2017-07-01 羅德製藥公司 抗破壞性立即釋出型調製劑類
US9993422B2 (en) 2012-04-18 2018-06-12 SpecGx LLC Immediate release, abuse deterrent pharmaceutical compositions
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2014011830A1 (fr) 2012-07-12 2014-01-16 Mallinckrodt Llc Compositions pharmaceutiques de dissuasion d'abus à libération prolongée
WO2014085599A1 (fr) 2012-11-30 2014-06-05 Acura Pharmaceuticals, Inc. Libération autorégulée de principe pharmaceutique actif
CN105120846B (zh) 2013-02-05 2019-10-18 普渡制药公司 抗篡改的药物制剂
WO2014146093A2 (fr) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Compositions anti-abus et méthodes d'utilisation
PL2968182T3 (pl) 2013-03-15 2018-10-31 SpecGx, LLC Zniechęcająca do nadużywania stała postać dawkowania dla natychmiastowego uwalniania z funkcjonalnym rowkiem
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
JP6445537B2 (ja) 2013-05-29 2018-12-26 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
AU2014356581C1 (en) 2013-11-26 2020-05-28 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
US20160310418A1 (en) 2013-12-11 2016-10-27 Sun Pharmaceutical Industries Limited Crush-resistant solid oral dosage form
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
US9642811B2 (en) 2014-03-26 2017-05-09 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
MX2016014738A (es) 2014-05-12 2017-03-06 Gruenenthal Gmbh Formulacion en capsula de liberacion inmediata resistente a alteraciones que comprende tapentadol.
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
HUE065006T2 (hu) 2014-07-03 2024-04-28 SpecGx LLC Nem-cellulóz poliszacharidokat tartalmazó, visszaélés-gátló, azonnali felszabadulású készítmények
CA2910865C (fr) 2014-07-15 2016-11-29 Isa Odidi Compositions et methodes destines a reduire les surdoses
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
JP2018517676A (ja) 2015-04-24 2018-07-05 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時放出および溶媒抽出に対する耐性を有する改変防止製剤
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
WO2017222575A1 (fr) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Procédé de préparation de formulations orales dissuasives d'abus plus stables
WO2020068510A1 (fr) 2018-09-25 2020-04-02 SpecGx LLC Formes posologiques de capsules à libération immédiate anti-abus

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE663600A (fr) * 1964-05-09 1965-11-08
GB1171691A (en) * 1967-02-24 1969-11-26 Forest Laboratories Lond-Acting Oral Carrier

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL25840A (en) * 1965-07-24 1969-12-31 Bayer Ag Optically active pyridine derivatives and their production
US3885027A (en) * 1971-04-12 1975-05-20 West Laboratories Inc Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3980766A (en) * 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE663600A (fr) * 1964-05-09 1965-11-08
GB1171691A (en) * 1967-02-24 1969-11-26 Forest Laboratories Lond-Acting Oral Carrier

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154414A1 (fr) 2010-06-07 2011-12-15 Ethypharm Microgranules et microcomprimes resistants au detournement

Also Published As

Publication number Publication date
DE2530563C2 (de) 1986-07-24
FR2361914B1 (fr) 1978-12-15
GB1517480A (en) 1978-07-12
BE843865A (fr) 1977-01-07
CA1064397A (fr) 1979-10-16
JPS5210415A (en) 1977-01-26
US4070494A (en) 1978-01-24
DE2530563A1 (de) 1977-01-27

Similar Documents

Publication Publication Date Title
FR2290912A1 (fr) Formulations pharmaceutiques contenant de la l-dopa ou ses derives
BE847742A (fr) Nouvelles imidazolidines, procede de preparation et compositions pharmaceutiques
NL7507268A (nl) Werkwijze ter bereiding van 1(alpha),24-dihydroxy-chole- calciferolen, alsmede derivaten en voorlopers daar- van , alsmede farmaceutische preparaten die deze ver- bindingen als actieve componenten bevatten.
BE845613A (fr) Preparations pharmaceutiques pour l'administration orale renfermant un ester-17beta de nandrolone et nouveaux esters- 17beta de nandrolone
ES460743A1 (es) Procedimiento para la obtencion de preparados medicinales con ph acido.
FR2457689A1 (fr) Medicament hypolipemique a base de carnitine
NL7608496A (nl) Werkwijze ter bereiding van farmacologisch actieve verbindingen alsmede farmaceutische preparaten die deze verbindingen bevatten.
IT1056094B (it) Composizione oftalmica in stato solido comprendente forme di dosaggio unitario di sostanze terapeuti camente attive e idrossipropilcellu losa e procedimento per la loro preparazione
BE819294A (fr) Nouvelles compositions pharmaceutiques contenant de l'acide n-(2-furfuryl)-4-chloro-5-sulfamoyl-antranilique et leur procede de preparation
FR2312243A1 (fr) Nouvelles propargyl-2-phenylamino-imidazolines-(2), leurs sels d'addition avec des acides, les medicaments les renfermant et procedes pour leur preparation
TR200001423T2 (tr) Erimiş paroksetin içeren yeni formülasyonlar
BE861141A (fr) Preparations pharmaceutiques a liberation soutenue des substances actives
FR2334345A1 (fr) Nouveau derive d'alcool benzylique, son procede de preparation et medicament le contenant
FR2321888A1 (fr) N-tetrahydrofurfuryl-noroxymorphones, leurs sels d'addition avec des acides, procedes pour leur preparation et medicaments en renfermant
FR2322591A1 (fr) Arylalkylamides, presentant une activite antidepressive, procede pour leur obtention et compositions pharmaceutiques les contenant
BE839533A (fr) 13,14-deshydro-11-desoxy-prostaglandines optiquement actives, leur preparation et leur emploi dans des compositions pharmaceutiques
CH487921A (fr) Procédé de préparation de nouvelles substances physiologiquement actives
PT65151A (fr) Procede pour la preparation de nouvelles solutions pharmaceutiques stables
BE848909A (fr) Nouvelles isothiourees, procede pour les preparer et compositions pharmaceutiques les contenant
FR2281106A1 (fr) Nouveaux composes arythmiques et compositions pharmaceutiques contenant ces composes comme substances actives
FR2315910A1 (fr) Compositions pharmaceutiques contenant de la " debrycine " heterocolloidale et procede pour leur preparation
BE889230A (fr) Nouveau medicaments veterinairespour hiniber le developpement des pro tozoaires et composition therapeutiques et formes pharmaceutiques contenant ces medicaments
US3173835A (en) Composition of n-acetyl-p-aminophenol and phenyltoloxamine for analgesia
FR2283670A1 (fr) Derives d'acides 19,20-bis-nor-prostanoique, leur preparation et compositions pharmaceutiques les contenant
FR2344545A1 (fr) Amides d'acides (2-pyrimidinylthio)-alcanoiques ayant une activite antilipemique, procedes pour leur preparation et compositions pharmaceutiques les contenant